EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors

Tyler W Buckner iD, Craig Kessler iD, Giancarlo Castaman iD, Cédric Hermans, Victor Jiménez-Yuste iD, Johnny Mahlangu iD, Wolfgang Miesbach iD, Johannes Oldenburg iD, Michael Recht, Leonard A Valentino, Allison P Wheeler, Steven W Pipe iD

Haemophilia · 2025

DOI: 10.1111/hae.70077 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Haemophilia, 2025. Verfasst von Tyler W Buckner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Factor VIIa, Hemophilia A, Hemophilia B, Hemorrhage. Die Arbeit nennt 21 Literaturangaben. Gefördert von: LFB SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Joint and muscle bleeding in persons with haemophilia (PwH) causes acute pain, an important patient‐reported outcome for evaluating treatment response. Eptacog beta is a recombinant activated human FVII bypassing agent approved for the treatment and control of bleeding in PwH A or B with inhibitors (PwHABI) ≥12 years using initial dose regimens (IDRs) of 75 or 225 µg/kg.

Aim

To evaluate pain reduction in PwHABI who treated bleeding episodes (BEs) with eptacog beta during the PERSEPT 1 trial.

Methods

PwHABI were randomly assigned to 75 or 225 µg/kg IDRs for BE treatment. Participants reported pain levels at predefined treatment evaluation timepoints using a visual analogue scale (VAS). Pain analyses were stratified by age, IDR assignment, and baseline pain levels. The diagnostic potential for using VAS pain score reductions to assess treatment response was explored using receiver operating characteristic (ROC) analysis.

Results

Five adolescents and 22 adults treated 468 BEs. Mean VAS scores decreased 30%–58% from baseline at 3 h post‐initial eptacog beta infusion amongst age and IDR categories, with further VAS score reductions observed through 24 h. PwHABI with high baseline BE pain showed larger absolute VAS score reductions before ending treatment than PwHABI experiencing mild BE pain. The optimum VAS score percentage reduction cutoff for predicting treatment outcomes was 44%.

Conclusion

Pain relief over 24 h was observed with eptacog beta treatment across IDR and age categories. This post hoc study demonstrates that percentage reduction from baseline VAS score influences perception of bleed resolution and can predict treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIaHemophilia AHemophilia BHemorrhagePainAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultPain ManagementPain MeasurementRecombinant ProteinsTreatment Outcome

Stichwörter der Autor:innen

PERSEPT 1eptacog betahaemophiliainhibitorspainrecombinant FVIIa

Substanzen

Factor VIIarecombinant FVIIaRecombinant Proteins

Autor:innen und Institutionen

  • Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA.
  • Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
  • Division of Hematology, Cliniques Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Hospital Universitario La Paz Idi-Paz, Autónoma University, Madrid, Spain.
  • Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa.

ORCID-Profile: Tyler W Buckner, Craig Kessler, Giancarlo Castaman, Victor Jiménez-Yuste, Johnny Mahlangu, Wolfgang Miesbach, Johannes Oldenburg, Steven W Pipe

Förderung

  • LFB SA

Zitieren

APA

Buckner, T. W., Kessler, C., Castaman, G., Hermans, C., Jiménez-Yuste, V., Mahlangu, J., Miesbach, W., Oldenburg, J., Recht, M., Valentino, L. A., Wheeler, A. P., & Pipe, S. W. (2025). Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors. Haemophilia. https://doi.org/10.1111/hae.70077

Vancouver

Buckner TW, Kessler C, Castaman G, Hermans C, Jiménez-Yuste V, Mahlangu J, et al. Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors. Haemophilia. 2025. doi:10.1111/hae.70077

BibTeX
@article{Buckner2025,
  author = {Buckner, Tyler W and Kessler, Craig and Castaman, Giancarlo and Hermans, Cédric and Jiménez-Yuste, Victor and Mahlangu, Johnny and Miesbach, Wolfgang and Oldenburg, Johannes and Recht, Michael and Valentino, Leonard A and Wheeler, Allison P and Pipe, Steven W},
  title = {Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70077}
}
Kostenlos starten →